Biomolecules & Therapeutics

The Korean Society of Applied Pharmacology (한국응용약물학회)
권호 표지
DOI QR코드

DOI QR Code

Sex Differences in the Preventive Effect of Cardiovascular and Metabolic Therapeutics on Dementia

  • Sun Ah Choi (Graduate School of Global Pharmaceutical Industry and Clinical Pharmacy, Ajou University) ;
  • Hye Jin Jee (AI-Super convergence KIURI Translational Research Center, Ajou University School of Medicine) ;
  • Katrina Joy Bormate (College of Pharmacy, Ajou University) ;
  • Yeonjae Kim (College of Pharmacy, Ajou University) ;
  • Yi-Sook Jung (Graduate School of Global Pharmaceutical Industry and Clinical Pharmacy, Ajou University)
  • Received : 2023.06.16
  • Accepted : 2023.09.17
  • Published : 2023.11.01
Download PDF
⟨ Previous Next ⟩

Abstract

Dementia is a clinical syndrome characterized by progressive impairment of cognitive and functional abilities. As currently applied treatments for dementia can only delay the progression of dementia and cannot fundamentally cure it, much attention is being paid to reducing its incidence by preventing the associated risk factors. Cardiovascular and metabolic diseases are well-known risk factors for dementia, and many studies have attempted to prevent dementia by treating these risk factors. Growing evidence suggests that sex-based factors may play an important role in the pathogenesis of dementia. Therefore, a deeper understanding of the differences in the effects of drugs based on sex may help improve their effectiveness. In this study, we reviewed sex differences in the impact of therapeutics targeting risk factors for dementia, such as cardiovascular and metabolic diseases, to prevent the incidence and/or progression of dementia.

Keywords

Acknowledgement

This research was partly supported by the Rural Development Administration (PJ01706804), the GRRC program of Gyeonggi province (GRRC Ajou2023-B01), and Korea Initiative for fostering University of Research and Innovation Program of the National Research Foundation (NRF) funded by the Korean government (MSIT) (No. NRF2021M3H1A104892211).

References

  1. Ancelin, M. L., Ripoche, E., Dupuy, A. M., Barberger-Gateau, P., Auriacombe, S., Rouaud, O., Berr, C., Carriere, I. and Ritchie, K. (2013) Sex differences in the associations between lipid levels and incident dementia. J. Alzheimers Dis. 34, 519-528. https://doi.org/10.3233/JAD-121228
  2. Annweiler, C., Herrmann, F. R., Fantino, B., Brugg, B. and Beauchet, O. (2012) Effectiveness of the combination of memantine plus vitamin D on cognition in patients with Alzheimer disease: a pre-post pilot study. Cogn. Behav. Neurol. 25, 121-127. https://doi.org/10.1097/WNN.0b013e31826df647
  3. Aronson, M. K., Ooi, W. L., Morgenstern, H., Hafner, A., Masur, D., Crystal, H., Frishman, W. H., Fisher, D. and Katzman, R. (1990) Women, myocardial infarction, and dementia in the very old. Neurology 40, 1102-1106. https://doi.org/10.1212/WNL.40.7.1102
  4. Barnes, L. L., Wilson, R. S., Bienias, J. L., Schneider, J. A., Evans, D. A. and Bennett, D. A. (2005) Sex differences in the clinical manifestations of Alzheimer disease pathology. Arch. Gen. Psychiatry 62, 685-691. https://doi.org/10.1001/archpsyc.62.6.685
  5. Barthold, D., Joyce, G., Wharton, W., Kehoe, P. and Zissimopoulos, J. (2018) The association of multiple anti-hypertensive medication classes with Alzheimer's disease incidence across sex, race, and ethnicity. PLoS One 13, e0206705.
  6. Batista, A. F., Forny-Germano, L., Clarke, J. R., Lyra, E. S. N. M., Brito-Moreira, J., Boehnke, S. E., Winterborn, A., Coe, B. C., Lablans, A., Vital, J. F., Marques, S. A., Martinez, A. M., Gralle, M., Holscher, C., Klein, W. L., Houzel, J. C., Ferreira, S. T., Munoz, D. P. and De Felice, F. G. (2018) The diabetes drug liraglutide reverses cognitive impairment in mice and attenuates insulin receptor and synaptic pathology in a non-human primate model of Alzheimer's disease. J. Pathol. 245, 85-100. https://doi.org/10.1002/path.5056
  7. Behl, T., Kaur, I., Sehgal, A., Singh, S., Sharma, N., Makeen, H. A., Albratty, M., Alhazmi, H. A., Felemban, S. G., Alsubayiel, A. M., Bhatia, S. and Bungau, S. (2022) "Aducanumab" making a comeback in Alzheimer's disease: an old wine in a new bottle. Biomed. Pharmacother. 148, 112746.
  8. Benz, V., Kintscher, U. and Foryst-Ludwig, A. (2012) Sex-specific differences in Type 2 Diabetes Mellitus and dyslipidemia therapy: PPAR agonists. Handb. Exp. Pharmacol. 387-410.
  9. Berger, J. S., Roncaglioni, M. C., Avanzini, F., Pangrazzi, I., Tognoni, G. and Brown, D. L. (2006) Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials. JAMA 295, 306-313. https://doi.org/10.1001/jama.295.3.306
  10. Blowey, D. L. (2016) Diuretics in the treatment of hypertension. Pediatr. Nephrol. 31, 2223-2233. https://doi.org/10.1007/s00467-016-3334-4
  11. Broadstock, M., Ballard, C. and Corbett, A. (2014) Latest treatment options for Alzheimer's disease, Parkinson's disease dementia and dementia with Lewy bodies. Expert Opin. Pharmacother. 15, 1797-1810. https://doi.org/10.1517/14656566.2014.936848
  12. Broe, G. A., Grayson, D. A., Creasey, H. M., Waite, L. M., Casey, B. J., Bennett, H. P., Brooks, W. S. and Halliday, G. M. (2000) Anti-inflammatory drugs protect against Alzheimer disease at low doses. Arch. Neurol. 57, 1586-1591.
  13. Budd Haeberlein, S., Aisen, P. S., Barkhof, F., Chalkias, S., Chen, T., Cohen, S., Dent, G., Hansson, O., Harrison, K., von Hehn, C., Iwatsubo, T., Mallinckrodt, C., Mummery, C. J., Muralidharan, K. K., Nestorov, I., Nisenbaum, L., Rajagovindan, R., Skordos, L., Tian, Y., van Dyck, C. H., Vellas, B., Wu, S., Zhu, Y. and Sandrock, A. (2022) Two randomized phase 3 studies of aducanumab in early Alzheimer's disease. J. Prev. Alzheimers Dis. 9, 197-210.
  14. Bunch, T. J., Bair, T. L., Crandall, B. G., Cutler, M. J., Day, J. D., Graves, K. G., Jacobs, V., Mallender, C., Osborn, J. S., Weiss, J. P. and May, H. T. (2020) Stroke and dementia risk in patients with and without atrial fibrillation and carotid arterial disease. Heart Rhythm. 17, 20-26. https://doi.org/10.1016/j.hrthm.2019.07.007
  15. Calabria, M., Geroldi, C., Lussignoli, G., Sabbatini, F. and Zanetti, O. (2009) Efficacy of acetyl-cholinesterase-inhibitor (ACHEI) treatment in Alzheimer's disease: a 21-month follow-up "real world" study. Arch. Gerontol. Geriatr. 49, e6-e11. https://doi.org/10.1016/j.archger.2008.07.006
  16. Campbell, I. W. (2004) Long-term glycaemic control with pioglitazone in patients with type 2 diabetes. Int. J. Clin. Pract. 58, 192-200. https://doi.org/10.1111/j.1368-5031.2004.0108.x
  17. Canevelli, M., Quarata, F., Remiddi, F., Lucchini, F., Lacorte, E., Vanacore, N., Bruno, G. and Cesari, M. (2017) Sex and gender differences in the treatment of Alzheimer's disease: a systematic review of randomized controlled trials. Pharmacol. Res. 115, 218-223. https://doi.org/10.1016/j.phrs.2016.11.035
  18. Chang, C. W., Horng, J. T., Hsu, C. C. and Chen, J. M. (2016) Mean daily dosage of aspirin and the risk of incident Alzheimer's dementia in patients with type 2 diabetes mellitus: a nationwide retrospective cohort study in Taiwan. J. Diabetes Res. 2016, 9027484.
  19. Chatterjee, S., Peters, S. A., Woodward, M., Mejia Arango, S., Batty, G. D., Beckett, N., Beiser, A., Borenstein, A. R., Crane, P. K., Haan, M., Hassing, L. B., Hayden, K. M., Kiyohara, Y., Larson, E. B., Li, C. Y., Ninomiya, T., Ohara, T., Peters, R., Russ, T. C., Seshadri, S., Strand, B. H., Walker, R., Xu, W. and Huxley, R. R. (2016) Type 2 diabetes as a risk factor for dementia in women compared with men: a pooled analysis of 2.3 million people comprising more than 100,000 cases of dementia. Diabetes Care 39, 300-307. https://doi.org/10.2337/dc15-1588
  20. Chen, J., Li, S., Sun, W. and Li, J. (2015) Anti-diabetes drug pioglitazone ameliorates synaptic defects in AD transgenic mice by inhibiting cyclin-dependent kinase5 activity. PLoS One 10, e0123864.
  21. Chou, P. S., Ho, B. L. and Yang, Y. H. (2017) Effects of pioglitazone on the incidence of dementia in patients with diabetes. J. Diabetes Complications 31, 1053-1057. https://doi.org/10.1016/j.jdiacomp.2017.01.006
  22. Chuang, T. J., Wang, Y. H., Wei, J. C. and Yeh, C. J. (2020) Association between use of anti-gout preparations and dementia: nested case-control nationwide population-based cohort study. Front. Med. (Lausanne) 7, 607808.
  23. Chuang, Y. F., Breitner, J. C. S., Chiu, Y. L., Khachaturian, A., Hayden, K., Corcoran, C., Tschanz, J., Norton, M., Munger, R., Welsh-Bohmer, K. and Zandi, P. P.; Cache County Investigators (2014) Use of diuretics is associated with reduced risk of Alzheimer's disease: the Cache County Study. Neurobiol. Aging 35, 2429-2435. https://doi.org/10.1016/j.neurobiolaging.2014.05.002
  24. Coker-Ayo, O. O., Nathaniel, S. I., Poupore, N., Bailey-Taylor, M. J., Roley, L. T., Goodwin, R. L., McPhail, B., Russ-Sellers, R. and Nathaniel, T. I. (2022) Sex differences in demographic and pharmacological factors in Alzheimer patients with dementia and cognitive impairments. Front. Behav. Neurosci. 16, 828782.
  25. Colca, J. R., McDonald, W. G. and Kletzien, R. F. (2014) Mitochondrial target of thiazolidinediones. Diabetes Obes. Metab. 16, 1048-1054. https://doi.org/10.1111/dom.12308
  26. Colombo, D., Caltagirone, C., Padovani, A., Sorbi, S., Spalletta, G., Simoni, L., Ori, A. and Zagni, E. (2018) Gender differences in neuropsychiatric symptoms in mild to moderate Alzheimer's disease patients undergoing switch of cholinesterase inhibitors: a post hoc analysis of the EVOLUTION study. J Womens Health (Larchmt) 27, 1368-1377. https://doi.org/10.1089/jwh.2017.6420
  27. Combs, C. K., Bates, P., Karlo, J. C. and Landreth, G. E. (2001) Regulation of β-amyloid stimulated proinflammatory responses by peroxisome proliferator-activated receptor α. Neurochem. Int. 39, 449-457. https://doi.org/10.1016/S0197-0186(01)00052-3
  28. Crane, J. and McGowan, B. (2016) The GLP-1 agonist, liraglutide, as a pharmacotherapy for obesity. Ther. Adv. Chronic Dis. 7, 92-107. https://doi.org/10.1177/2040622315620180
  29. Cummings, J., Aisen, P., Apostolova, L. G., Atri, A., Salloway, S. and Weiner, M. (2021) Aducanumab: appropriate use recommendations. J. Prev. Alzheimers Dis. 8, 398-410.
  30. Dalbeth, N., Choi, H. K., Joosten, L. A. B., Khanna, P. P., Matsuo, H., Perez-Ruiz, F. and Stamp, L. K. (2019) Gout. Nat. Rev. Dis. Primers 5, 69.
  31. Danysz, W., Parsons, C. G., Mobius, H. J., Stoffler, A. and Quack, G. (2000) Neuroprotective and symptomatological action of memantine relevant for Alzheimer's disease--a unified glutamatergic hypothesis on the mechanism of action. Neurotox. Res. 2, 85-97. https://doi.org/10.1007/BF03033787
  32. de Bruijn, R. F., Heeringa, J., Wolters, F. J., Franco, O. H., Stricker, B. H., Hofman, A., Koudstaal, P. J. and Ikram, M. A. (2015) Association between atrial fibrillation and dementia in the general population. JAMA Neurol. 72, 1288-1294. https://doi.org/10.1001/jamaneurol.2015.2161
  33. de Vries, S. T., Denig, P., Ekhart, C., Mol, P. G. M. and van Puijenbroek, E. P. (2020) Sex differences in adverse drug reactions of metformin: a longitudinal survey study. Drug Saf. 43, 489-495. https://doi.org/10.1007/s40264-020-00913-8
  34. Dentali, F., Sironi, A. P., Gianni, M., Orlandini, F., Guasti, L., Grandi, A. M., Franchini, M., Ageno, W. and Squizzato, A. (2015) Gender difference in efficacy and safety of nonvitamin K antagonist oral anticoagulants in patients with nonvalvular atrial fibrillation or venous thromboembolism: a systematic review and a meta-analysis of the literature. Semin. Thromb. Hemost. 41, 774-787. https://doi.org/10.1055/s-0035-1564042
  35. Derosa, G. and Maffioli, P. (2012) α-Glucosidase inhibitors and their use in clinical practice. Arch. Med. Sci. 8, 899-906. https://doi.org/10.5114/aoms.2012.31621
  36. Dickson, S. L., Shirazi, R. H., Hansson, C., Bergquist, F., Nissbrandt, H. and Skibicka, K. P. (2012) The glucagon-like peptide 1 (GLP-1) analogue, exendin-4, decreases the rewarding value of food: a new role for mesolimbic GLP-1 receptors. J. Neurosci. 32, 4812-4820. https://doi.org/10.1523/JNEUROSCI.6326-11.2012
  37. DiNicolantonio, J. J., Bhutani, J. and O'Keefe, J. H. (2015) Acarbose: safe and effective for lowering postprandial hyperglycaemia and improving cardiovascular outcomes. Open Heart 2, e000327.
  38. Duarte, A. I., Moreira, P. I. and Oliveira, C. R. (2012) Insulin in central nervous system: more than just a peripheral hormone. J. Aging Res. 2012, 384017.
  39. Elias, M. F., Elias, P. K., Sullivan, L. M., Wolf, P. A. and D'Agostino, R. B. (2003) Lower cognitive function in the presence of obesity and hypertension: the Framingham heart study. Int. J. Obes. Relat. Metab. Disord. 27, 260-268. https://doi.org/10.1038/sj.ijo.802225
  40. Ellison, G. (1995) The N-methyl-D-aspartate antagonists phencyclidine, ketamine and dizocilpine as both behavioral and anatomical models of the dementias. Brain Res. Brain Res. Rev. 20, 250-267. https://doi.org/10.1016/0165-0173(94)00014-G
  41. Esteghamati, A., Noshad, S., Rabizadeh, S., Ghavami, M., Zandieh, A. and Nakhjavani, M. (2013) Comparative effects of metformin and pioglitazone on omentin and leptin concentrations in patients with newly diagnosed diabetes: a randomized clinical trial. Regul. Pept. 182, 1-6. https://doi.org/10.1016/j.regpep.2012.12.005
  42. Fazal, K., Perera, G., Khondoker, M., Howard, R. and Stewart, R. (2017) Associations of centrally acting ACE inhibitors with cognitive decline and survival in Alzheimer's disease. BJPsych Open 3, 158-164. https://doi.org/10.1192/bjpo.bp.116.004184
  43. Feigin, V., Ratnasabapathy, Y. and Anderson, C. (2005) Does blood pressure lowering treatment prevents dementia or cognitive decline in patients with cardiovascular and cerebrovascular disease? J. Neurol. Sci. 229-230, 151-155. https://doi.org/10.1016/j.jns.2004.11.020
  44. Feldman, L., Vinker, S., Efrati, S., Beberashvili, I., Gorelik, O., Wasser, W. and Shani, M. (2016) Amlodipine treatment of hypertension associates with a decreased dementia risk. Clin. Exp. Hypertens. 38, 545-549. https://doi.org/10.3109/10641963.2016.1174249
  45. Ferris, S., Lane, R., Sfikas, N., Winblad, B., Farlow, M. and Feldman, H. H. (2009) Effects of gender on response to treatment with rivastigmine in mild cognitive impairment: a post hoc statistical modeling approach. Gend. Med. 6, 345-355. https://doi.org/10.1016/j.genm.2009.06.004
  46. Giacobini, E. and Pepeu, G. (2018) Sex and gender differences in the brain cholinergic system and in the response to therapy of Alzheimer disease with cholinesterase inhibitors. Curr. Alzheimer Res. 15, 1077-1084. https://doi.org/10.2174/1567205015666180613111504
  47. Giannopoulos, S., Katsanos, A. H., Tsivgoulis, G. and Marshall, R. S. (2012) Statins and cerebral hemodynamics. J. Cereb. Blood Flow Metab. 32, 1973-1976. https://doi.org/10.1038/jcbfm.2012.122
  48. Gilsanz, P., Mayeda, E. R., Glymour, M. M., Quesenberry, C. P., Mungas, D. M., DeCarli, C., Dean, A. and Whitmer, R. A. (2017) Female sex, early-onset hypertension, and risk of dementia. Neurology 89, 1886-1893. https://doi.org/10.1212/WNL.0000000000004602
  49. Gu, Q., Burt, V. L., Paulose-Ram, R. and Dillon, C. F. (2008) Gender differences in hypertension treatment, drug utilization patterns, and blood pressure control among US adults with hypertension: data from the National Health and Nutrition Examination Survey 1999-2004. Am. J. Hypertens. 21, 789-798. https://doi.org/10.1038/ajh.2008.185
  50. Harris, D. J. and Douglas, P. S. (2000) Enrollment of women in cardiovascular clinical trials funded by the National Heart, Lung, and Blood Institute. N. Engl. J. Med. 343, 475-480. https://doi.org/10.1056/NEJM200008173430706
  51. Harrison, D. E., Strong, R., Allison, D. B., Ames, B. N., Astle, C. M., Atamna, H., Fernandez, E., Flurkey, K., Javors, M. A., Nadon, N. L., Nelson, J. F., Pletcher, S., Simpkins, J. W., Smith, D., Wilkinson, J. E. and Miller, R. A. (2014) Acarbose, 17-α-estradiol, and nordihydroguaiaretic acid extend mouse lifespan preferentially in males. Aging Cell 13, 273-282. https://doi.org/10.1111/acel.12170
  52. Harrold, L. R., Yood, R. A., Mikuls, T. R., Andrade, S. E., Davis, J., Fuller, J., Chan, K. A., Roblin, D., Raebel, M. A., Von Worley, A., Platt, R. and Saag, K. G. (2006) Sex differences in gout epidemiology: evaluation and treatment. Ann. Rheum. Dis. 65, 1368-1372. https://doi.org/10.1136/ard.2006.051649
  53. Ho, J. K., Moriarty, F., Manly, J. J., Larson, E. B., Evans, D. A., Rajan, K. B., Hudak, E. M., Hassan, L., Liu, E., Sato, N., Hasebe, N., Laurin, D., Carmichael, P. H. and Nation, D. A. (2021) Blood-brain barrier crossing renin-angiotensin drugs and cognition in the elderly: a meta-analysis. Hypertension 78, 629-643. https://doi.org/10.1161/HYPERTENSIONAHA.121.17049
  54. Hsu, J. Y., Liu, P. P., Liu, A. B., Lin, S. M., Huang, H. K. and Loh, C. H. (2021) Lower risk of dementia in patients with atrial fibrillation taking non-vitamin K antagonist oral anticoagulants: a nationwide population-based cohort study. J. Am. Heart Assoc. 10, e016437.
  55. Hsu, P. F., Sung, S. H., Cheng, H. M., Shin, S. J., Lin, K. D., Chong, K., Yen, F. S., Yu, B. H., Huang, C. T. and Hsu, C. C. (2018) Cardiovascular benefits of acarbose vs sulfonylureas in patients with type 2 diabetes treated with metformin. J. Clin. Endocrinol. Metab. 103, 3611-3619. https://doi.org/10.1210/jc.2018-00040
  56. Hwang, J., Yoo, J. A., Yoon, H., Han, T., Yoon, J., An, S., Cho, J. Y. and Lee, J. (2021) The role of leptin in the association between obesity and psoriasis. Biomol. Ther. (Seoul) 29, 11-21. https://doi.org/10.4062/biomolther.2020.054
  57. Institute of Medicine Committee on Social Security Cardiovascular Disability, C. (2010) Cardiovascular Disability: Updating the Social Security Listings. National Academies Press (US), Washington (DC).
  58. Jacobson, S. A. and Sabbagh, M. N. (2008) Donepezil: potential neuroprotective and disease-modifying effects. Expert Opin. Drug Metab. Toxicol. 4, 1363-1369. https://doi.org/10.1517/17425255.4.10.1363
  59. Justin, B. N., Turek, M. and Hakim, A. M. (2013) Heart disease as a risk factor for dementia. Clin. Epidemiol. 5, 135-145.
  60. Kalar, I., Xu, H., Secnik, J., Schwertner, E., Kramberger, M. G., Winblad, B., von Euler, M., Eriksdotter, M. and Garcia-Ptacek, S. (2021) Calcium channel blockers, survival and ischaemic stroke in patients with dementia: a Swedish registry study. J. Intern. Med. 289, 508-522. https://doi.org/10.1111/joim.13170
  61. Kalibala, J., Pechere-Bertschi, A. and Desmeules, J. (2020) Gender differences in cardiovascular pharmacotherapy-the example of hypertension: a mini review. Front. Pharmacol. 11, 564.
  62. Kapoor, E., Collazo-Clavell, M. L. and Faubion, S. S. (2017) Weight gain in women at midlife: a concise review of the pathophysiology and strategies for management. Mayo Clin. Proc. 92, 1552-1558. https://doi.org/10.1016/j.mayocp.2017.08.004
  63. Kastarinen, M. J., Nissinen, A. M., Vartiainen, E. A., Jousilahti, P. J., Korhonen, H. J., Puska, P. M. and Tuomilehto. (2000) Blood pressure levels and obesity trends in hypertensive and normotensive Finnish population from 1982 to 1997. J. Hypertens. 18, 255-262. https://doi.org/10.1097/00004872-200018030-00003
  64. Khosravan, R., Kukulka, M. J., Wu, J. T., Joseph-Ridge, N. and Vernillet, L. (2008) The effect of age and gender on pharmacokinetics, pharmacodynamics, and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase. J. Clin. Pharmacol. 48, 1014-1024. https://doi.org/10.1177/0091270008322035
  65. Kim, D., Yang, P. S., Jang, E., Yu, H. T., Kim, T. H., Uhm, J. S., Kim, J. Y., Sung, J. H., Pak, H. N., Lee, M. H., Lip, G. Y. H. and Joung, B. (2021) Association of anticoagulant therapy with risk of dementia among patients with atrial fibrillation. Europace 23, 184-195. https://doi.org/10.1093/europace/euaa192
  66. Kim, D., Yang, P. S., Yu, H. T., Kim, T. H., Jang, E., Sung, J. H., Pak, H. N., Lee, M. Y., Lee, M. H., Lip, G. Y. H. and Joung, B. (2019) Risk of dementia in stroke-free patients diagnosed with atrial fibrillation: data from a population-based cohort. Eur. Heart J. 40, 2313-2323. https://doi.org/10.1093/eurheartj/ehz386
  67. Kim, H. C. (2021) Epidemiology of cardiovascular disease and its risk factors in Korea. Glob. Health Med. 3, 134-141. https://doi.org/10.35772/ghm.2021.01008
  68. Kim, M. Y., Jung, M., Noh, Y., Shin, S., Hong, C. H., Lee, S. and Jung, Y. S. (2020) Impact of statin use on dementia incidence in elderly men and women with ischemic heart disease. Biomedicines 8, 30.
  69. Kim, M. Y., Noh, Y., Son, S. J., Shin, S., Paik, H. Y., Lee, S. and Jung, Y. S. (2018) Effect of cilostazol on incident dementia in elderly men and women with ischemic heart disease. J. Alzheimers Dis. 63, 635-644. https://doi.org/10.3233/JAD-170895
  70. Kimm, H., Lee, P. H., Shin, Y. J., Park, K. S., Jo, J., Lee, Y., Kang, H. C. and Jee, S. H. (2011) Mid-life and late-life vascular risk factors and dementia in Korean men and women. Arch. Gerontol. Geriatr. 52, e117-e122. https://doi.org/10.1016/j.archger.2010.09.004
  71. Kinney, J. W., Bemiller, S. M., Murtishaw, A. S., Leisgang, A. M., Salazar, A. M. and Lamb, B. T. (2018) Inflammation as a central mechanism in Alzheimer's disease. Alzheimers Dement. (N. Y.) 4, 575-590. https://doi.org/10.1016/j.trci.2018.06.014
  72. Klonoff, D. C., Buse, J. B., Nielsen, L. L., Guan, X., Bowlus, C. L., Holcombe, J. H., Wintle, M. E. and Maggs, D. G. (2008) Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr. Med. Res. Opin. 24, 275-286. https://doi.org/10.1185/030079908X253870
  73. Kuan, Y. C., Huang, K. W., Yen, D. J., Hu, C. J., Lin, C. L. and Kao, C. H. (2016) Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers reduced dementia risk in patients with diabetes mellitus and hypertension. Int. J. Cardiol. 220, 462-466. https://doi.org/10.1016/j.ijcard.2016.06.215
  74. Kuo, C. F., Grainge, M. J., Zhang, W. and Doherty, M. (2015) Global epidemiology of gout: prevalence, incidence and risk factors. Nat. Rev. Rheumatol. 11, 649-662. https://doi.org/10.1038/nrrheum.2015.91
  75. Kuwabara, M., Kondo, F., Hamada, T., Takahashi, J. I., Takenaka, N. and Furuno, T. (2016) Impact of statins therapy for ischemic heart disease patients with low-density lipoprotein cholesterol levels less than 100 mg/dL. Acta Cardiol. Sin. 32, 565-569.
  76. Lai, S. W., Liao, K. F., Kuo, Y. H., Liu, C. S. and Hwang, B. F. (2022) Comparison of benzbromarone and allopurinol on primary prevention of the first gout flare in asymptomatic hyperuricemia. J. Pers. Med. 12, 697.
  77. Li, D. D., Zhang, Y. H., Zhang, W. and Zhao, P. (2019) Meta-analysis of randomized controlled trials on the efficacy and safety of donepezil, galantamine, rivastigmine, and memantine for the treatment of Alzheimer's disease. Front. Neurosci. 13, 472.
  78. Li, H., Li, W., Zhang, X., Ma, X. C. and Zhang, R. W. (2020) Aspirin use on incident dementia and mild cognitive decline: a systematic review and meta-analysis. Front. Aging Neurosci. 12, 578071.
  79. Li, J., Li, J., Shan, Z., Yang, W., Liu, J., Tian, H., Zhou, Z., Ji, Q., Weng, J., Jia, W., Lu, J., Liu, J., Xu, Y. and Yang, Z. (2021) Gender-differential effects on blood glucose levels between acarbose and metformin in Chinese patients with newly diagnosed type 2 diabetes: a sub-analysis of the MARCH trial. Endocr. J. 68, 69-79. https://doi.org/10.1507/endocrj.EJ20-0006
  80. Li, N. C., Lee, A., Whitmer, R. A., Kivipelto, M., Lawler, E., Kazis, L. E. and Wolozin, B. (2010) Use of angiotensin receptor blockers and risk of dementia in a predominantly male population: prospective cohort analysis. BMJ 340, b5465.
  81. Li, W., Qiu, Q., Sun, L., Yue, L., Wang, T., Li, X. and Xiao, S. (2017) Sex differences in obesity and cognitive function in a cognitively normal aging Chinese Han population. Neuropsychiatr. Dis. Treat. 13, 2405-2410. https://doi.org/10.2147/NDT.S145245
  82. Lipton, S. A. and Rosenberg, P. A. (1994) Excitatory amino acids as a final common pathway for neurologic disorders. N. Engl. J. Med. 330, 613-622. https://doi.org/10.1056/NEJM199403033300907
  83. Liu, L., Zhang, C., Lv, X., Lai, X., Xu, L., Feng, J., Song, Y., Wang, S. and Zhan, S. (2020) Sex-specific associations between lipids and cognitive decline in the middle-aged and elderly: a cohort study of Chinese adults. Alzheimers Res. Ther. 12, 164.
  84. Lovejoy, J. C. and Sainsbury, A.; Stock Conference Working Group (2009) Sex differences in obesity and the regulation of energy homeostasis. Obes. Rev. 10, 154-167. https://doi.org/10.1111/j.1467-789X.2008.00529.x
  85. Lu, C. H., Yang, C. Y., Li, C. Y., Hsieh, C. Y. and Ou, H. T. (2018) Lower risk of dementia with pioglitazone, compared with other second-line treatments, in metformin-based dual therapy: a population-based longitudinal study. Diabetologia 61, 562-573. https://doi.org/10.1007/s00125-017-4499-5
  86. MacGowan, S. H., Wilcock, G. K. and Scott, M. (1998) Effect of gender and apolipoprotein E genotype on response to anticholinesterase therapy in Alzheimer's disease. Int. J. Geriatr. Psychiatry 13, 625-630. https://doi.org/10.1002/(SICI)1099-1166(199809)13:9<625::AID-GPS835>3.0.CO;2-2
  87. Mangmool, S., Denkaew, T., Parichatikanond, W. and Kurose, H. (2017) β-Adrenergic receptor and insulin resistance in the heart. Biomol. Ther. (Seoul) 25, 44-56. https://doi.org/10.4062/biomolther.2016.128
  88. Marucci, G., Buccioni, M., Ben, D. D., Lambertucci, C., Volpini, R. and Amenta, F. (2021) Efficacy of acetylcholinesterase inhibitors in Alzheimer's disease. Neuropharmacology 190, 108352.
  89. Matsumoto, C., Ogawa, H., Saito, Y., Okada, S., Soejima, H., Sakuma, M., Masuda, I., Nakayama, M., Doi, N., Jinnouchi, H., Waki, M. and Morimoto, T. (2020) Sex difference in effects of low-dose aspirin on prevention of dementia in patients with type 2 diabetes: a long-term follow-up study of a randomized clinical trial. Diabetes Care 43, 314-320. https://doi.org/10.2337/dc19-1188
  90. McShane, R., Westby, M. J., Roberts, E., Minakaran, N., Schneider, L., Farrimond, L. E., Maayan, N., Ware, J. and Debarros, J. (2019) Memantine for dementia. Cochrane Database Syst. Rev. 3, CD003154.
  91. Miao, Z., Li, C., Chen, Y., Zhao, S., Wang, Y., Wang, Z., Chen, X., Xu, F., Wang, F., Sun, R., Hu, J., Song, W., Yan, S. and Wang, C. Y. (2008) Dietary and lifestyle changes associated with high prevalence of hyperuricemia and gout in the Shandong coastal cities of Eastern China. J. Rheumatol. 35, 1859-1864.
  92. Mielke, M. M., Zandi, P. P., Blennow, K., Gustafson, D., Sjogren, M., Rosengren, L. and Skoog, I. (2006) Low serum potassium in mid life associated with decreased cerebrospinal fluid Abeta42 in late life. Alzheimer Dis. Assoc. Disord. 20, 30-36. https://doi.org/10.1097/01.wad.0000201848.67954.7d
  93. Mullins, R. J., Mustapic, M., Chia, C. W., Carlson, O., Gulyani, S., Tran, J., Li, Y., Mattson, M. P., Resnick, S., Egan, J. M., Greig, N. H. and Kapogiannis, D. (2019) A pilot study of exenatide actions in Alzheimer's disease. Curr. Alzheimer Res. 16, 741-752. https://doi.org/10.2174/1567205016666190913155950
  94. Natesan, V. and Kim, S. J. (2023) The trend of organic based nanoparticles in the treatment of diabetes and its perspectives. Biomol. Ther. (Seoul) 31, 16-26. https://doi.org/10.4062/biomolther.2022.080
  95. Newman, A. B., Fitzpatrick, A. L., Lopez, O., Jackson, S., Lyketsos, C., Jagust, W., Ives, D., Dekosky, S. T. and Kuller, L. H. (2005) Dementia and Alzheimer's disease incidence in relationship to cardiovascular disease in the Cardiovascular Health Study cohort. J. Am. Geriatr. Soc. 53, 1101-1107. https://doi.org/10.1111/j.1532-5415.2005.53360.x
  96. Ng, T. P., Feng, L., Yap, K. B., Lee, T. S., Tan, C. H. and Winblad, B. (2014) Long-term metformin usage and cognitive function among older adults with diabetes. J. Alzheimers Dis. 41, 61-68. https://doi.org/10.3233/JAD-131901
  97. Nimmrich, V. and Eckert, A. (2013) Calcium channel blockers and dementia. Br. J. Pharmacol. 169, 1203-1210. https://doi.org/10.1111/bph.12240
  98. Norgaard, C. H., Friedrich, S., Hansen, C. T., Gerds, T., Ballard, C., Moller, D. V., Knudsen, L. B., Kvist, K., Zinman, B., Holm, E., Torp-Pedersen, C. and Morch, L. S. (2022) Treatment with glucagon-like peptide-1 receptor agonists and incidence of dementia: data from pooled double-blind randomized controlled trials and nationwide disease and prescription registers. Alzheimers Dement. (N. Y.) 8, e12268.
  99. Olmastroni, E., Molari, G., De Beni, N., Colpani, O., Galimberti, F., Gazzotti, M., Zambon, A., Catapano, A. L. and Casula, M. (2022) Statin use and risk of dementia or Alzheimer's disease: a systematic review and meta-analysis of observational studies. Eur. J. Prev. Cardiol. 29, 804-814. https://doi.org/10.1093/eurjpc/zwab208
  100. Onishi, Y., Oura, T., Matsui, A., Matsuura, J. and Iwamoto, N. (2017) Analysis of efficacy and safety of dulaglutide 0.75 mg stratified by sex in patients with type 2 diabetes in 2 randomized, controlled phase 3 studies in Japan. Endocr. J. 64, 553-560. https://doi.org/10.1507/endocrj.EJ16-0552
  101. Ono, K. and Tsuji, M. (2019) Pharmacological potential of cilostazol for Alzheimer's disease. Front. Pharmacol. 10, 559.
  102. Oveisgharan, S., Arvanitakis, Z., Yu, L., Farfel, J., Schneider, J. A. and Bennett, D. A. (2018) Sex differences in Alzheimer's disease and common neuropathologies of aging. Acta Neuropathol. 136, 887-900. https://doi.org/10.1007/s00401-018-1920-1
  103. Overgaard, R. V., Petri, K. C., Jacobsen, L. V. and Jensen, C. B. (2016) Liraglutide 3.0 mg for weight management: a population pharmacokinetic analysis. Clin. Pharmacokinet. 55, 1413-1422. https://doi.org/10.1007/s40262-016-0410-7
  104. Paul, C., Baby, M., Anthraper, A. R. and K. K. (2020) NOACs: an emerging class of oral anticoagulants-a review article. Future J. Pharm. Sci. 6, 95.
  105. Pencek, R., Blickensderfer, A., Li, Y., Brunell, S. C. and Anderson, P. W. (2012) Exenatide twice daily: analysis of effectiveness and safety data stratified by age, sex, race, duration of diabetes, and body mass index. Postgrad. Med. 124, 21-32.
  106. Perry, T. and Greig, N. H. (2005) Enhancing central nervous system endogenous GLP-1 receptor pathways for intervention in Alzheimer's disease. Curr. Alzheimer Res. 2, 377-385. https://doi.org/10.2174/1567205054367892
  107. Poly, T. N., Islam, M. M., Walther, B. A., Yang, H. C., Wu, C. C., Lin, M. C. and Li, Y. C. (2020) Association between use of statin and risk of dementia: a meta-analysis of observational studies. Neuroepidemiology 54, 214-226. https://doi.org/10.1159/000503105
  108. Porter, J. W., Barnas, J. L., Welly, R., Spencer, N., Pitt, J., Vieira-Potter, V. J. and Kanaley, J. A. (2020) Age, sex, and depot-specific differences in adipose-tissue estrogen receptors in individuals with obesity. Obesity (Silver Spring) 28, 1698-1707. https://doi.org/10.1002/oby.22888
  109. Prins, N. D. and Scheltens, P. (2013) Treating Alzheimer's disease with monoclonal antibodies: current status and outlook for the future. Alzheimers Res. Ther. 5, 56.
  110. Querfurth, H. W. and LaFerla, F. M. (2010) Alzheimer's disease. N. Engl. J. Med. 362, 329-344. https://doi.org/10.1056/NEJMra0909142
  111. Rena, G., Pearson, E. R. and Sakamoto, K. (2013) Molecular mechanism of action of metformin: old or new insights? Diabetologia 56, 1898-1906. https://doi.org/10.1007/s00125-013-2991-0
  112. Rosano, G. M., Lewis, B., Agewall, S., Wassmann, S., Vitale, C., Schmidt, H., Drexel, H., Patak, A., Torp-Pedersen, C., Kjeldsen, K. P. and Tamargo, J. (2015) Gender differences in the effect of cardiovascular drugs: a position document of the Working Group on Pharmacology and Drug Therapy of the ESC. Eur. Heart J. 36, 2677-2680. https://doi.org/10.1093/eurheartj/ehv161
  113. Roush, G. C., Kaur, R. and Ernst, M. E. (2014) Diuretics: a review and update. J. Cardiovasc. Pharmacol. Ther. 19, 5-13. https://doi.org/10.1177/1074248413497257
  114. Samaras, K., Makkar, S., Crawford, J. D., Kochan, N. A., Wen, W., Draper, B., Trollor, J. N., Brodaty, H. and Sachdev, P. S. (2020) Metformin use is associated with slowed cognitive decline and reduced incident dementia in older adults with type 2 diabetes: the Sydney Memory and Ageing Study. Diabetes Care 43, 2691-2701. https://doi.org/10.2337/dc20-0892
  115. Santilli, F., Simeone, P. G., Guagnano, M. T., Leo, M., Maccarone, M. T., Di Castelnuovo, A., Sborgia, C., Bonadonna, R. C., Angelucci, E., Federico, V., Cianfarani, S., Manzoli, L., Davi, G., Tartaro, A. and Consoli, A. (2017) Effects of liraglutide on weight loss, fat distribution, and β-cell function in obese subjects with prediabetes or early type 2 diabetes. Diabetes Care 40, 1556-1564. https://doi.org/10.2337/dc17-0589
  116. Scacchi, R., Gambina, G., Broggio, E. and Corbo, R. M. (2014) Sex and ESR1 genotype may influence the response to treatment with donepezil and rivastigmine in patients with Alzheimer's disease. Int. J. Geriatr. Psychiatry 29, 610-615. https://doi.org/10.1002/gps.4043
  117. Secher, A., Jelsing, J., Baquero, A. F., Hecksher-Sorensen, J., Cowley, M. A., Dalboge, L. S., Hansen, G., Grove, K. L., Pyke, C., Raun, K., Schaffer, L., Tang-Christensen, M., Verma, S., Witgen, B. M., Vrang, N. and Bjerre Knudsen, L. (2014) The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss. J. Clin. Invest. 124, 4473-4488. https://doi.org/10.1172/JCI75276
  118. Shi, M., Chu, F., Zhu, F. and Zhu, J. (2022) Impact of anti-amyloid-beta monoclonal antibodies on the pathology and clinical profile of Alzheimer's disease: a focus on aducanumab and lecanemab. Front. Aging Neurosci. 14, 870517.
  119. Silva, M. V. F., Loures, C. M. G., Alves, L. C. V., de Souza, L. C., Borges, K. B. G. and Carvalho, M. D. G. (2019) Alzheimer's disease: risk factors and potentially protective measures. J. Biomed. Sci. 26, 33.
  120. Singh, J. A. and Cleveland, J. D. (2018a) Comparative effectiveness of allopurinol versus febuxostat for preventing incident dementia in older adults: a propensity-matched analysis. Arthritis Res. Ther. 20, 167.
  121. Singh, J. A. and Cleveland, J. D. (2018b) Gout and dementia in the elderly: a cohort study of Medicare claims. BMC Geriatr. 18, 281.
  122. Singh, J. A. and Cleveland, J. D. (2018c) Use of urate-lowering therapies is not associated with an increase in the risk of incident dementia in older adults. Ann. Rheum. Dis. 77, 1243-1245. https://doi.org/10.1136/annrheumdis-2017-212638
  123. Singh, R., Barden, A., Mori, T. and Beilin, L. (2001) Advanced glycation end-products: a review. Diabetologia 44, 129-146. https://doi.org/10.1007/s001250051591
  124. Song, M. S., Rauw, G., Baker, G. B. and Kar, S. (2008) Memantine protects rat cortical cultured neurons against beta-amyloid-induced toxicity by attenuating tau phosphorylation. Eur. J. Neurosci. 28, 1989-2002. https://doi.org/10.1111/j.1460-9568.2008.06498.x
  125. Stern, N., Grosskopf, I., Shapira, I., Kisch, E., Isaacov, A., Limor, R., Baz, M., Leshem, Y., Flatau, E., Miller, A. and Greenman, Y. (2000) Risk factor clustering in hypertensive patients: impact of the reports of NCEP-II and second joint task force on coronary prevention on JNC-VI guidelines. J. Intern. Med. 248, 203-210. https://doi.org/10.1046/j.1365-2796.2000.00724.x
  126. Suh, G. H., Yeon Jung, H., Uk Lee, C., Hoon Oh, B., Nam Bae, J., Jung, H. Y., Ju, Y. S., Kil Yeon, B., Park, J., Hong, I., Choi, S. and Ho Lee, J. (2004) A prospective, double-blind, community-controlled comparison of three doses of galantamine in the treatment of mild to moderate Alzheimer's disease in a Korean population. Clin. Ther. 26, 1608-1618. https://doi.org/10.1016/j.clinthera.2004.10.006
  127. Szeto, Y. Y. J. and Lewis, J. G. S. (2016) Current treatment options for Alzheimer's disease and Parkinson's disease dementia. Curr. Neuropharmacol. 14, 326-338. https://doi.org/10.2174/1570159X14666151208112754
  128. Tai, S. Y., Chen, C. H., Chien, C. Y. and Yang, Y. H. (2017) Cilostazol as an add-on therapy for patients with Alzheimer's disease in Taiwan: a case control study. BMC Neurol. 17, 40.
  129. Tai, X. Y., Veldsman, M., Lyall, D. M., Littlejohns, T. J., Langa, K. M., Husain, M., Ranson, J. and Llewellyn, D. J. (2022) Cardiometabolic multimorbidity, genetic risk, and dementia: a prospective cohort study. Lancet Healthy Longev. 3, e428-e436. https://doi.org/10.1016/S2666-7568(22)00117-9
  130. Thambisetty, M. and Howard, R. (2023) Lecanemab trial in AD brings hope but requires greater clarity. Nat. Rev. Neurol. 19, 132-133. https://doi.org/10.1038/s41582-022-00768-w
  131. Thoenes, M., Neuberger, H. R., Volpe, M., Khan, B. V., Kirch, W. and Bohm, M. (2010) Antihypertensive drug therapy and blood pressure control in men and women: an international perspective. J. Hum. Hypertens. 24, 336-344. https://doi.org/10.1038/jhh.2009.76
  132. Tramunt, B., Smati, S., Grandgeorge, N., Lenfant, F., Arnal, J. F., Montagner, A. and Gourdy, P. (2020) Sex differences in metabolic regulation and diabetes susceptibility. Diabetologia 63, 453-461. https://doi.org/10.1007/s00125-019-05040-3
  133. Tseng, C. H. (2020) Dementia risk in type 2 diabetes patients: acarbose use and its joint effects with metformin and pioglitazone. Aging Dis. 11, 658-667. https://doi.org/10.14336/AD.2019.0621
  134. Vadini, F., Simeone, P. G., Boccatonda, A., Guagnano, M. T., Liani, R., Tripaldi, R., Di Castelnuovo, A., Cipollone, F., Consoli, A. and Santilli, F. (2020) Liraglutide improves memory in obese patients with prediabetes or early type 2 diabetes: a randomized, controlled study. Int. J. Obes. (Lond.) 44, 1254-1263. https://doi.org/10.1038/s41366-020-0535-5
  135. van Dyck, C. H. (2018) Anti-amyloid-beta monoclonal antibodies for Alzheimer's disease: pitfalls and promise. Biol. Psychiatry 83, 311-319. https://doi.org/10.1016/j.biopsych.2017.08.010
  136. Vaughan, C. J., Gotto, A. M. and Basson, C. T. (2000) The evolving role of statins in the management of atherosclerosis. J. Am. Coll. Cardiol. 35, 1-10. https://doi.org/10.1016/S0735-1097(99)00525-2
  137. Veenstra, F., Wanten, S. A. C., Verhoef, L. M., Ter Stal, M., Kwok, W. Y., van den Hoogen, F. H. J., Flendrie, M. and van Herwaarden, N. (2021) Sex differences in response to allopurinol and benzbromarone in gout: a retrospective cohort study. Rheumatol. Adv. Pract. 5, rkab002.
  138. Verger, A., Yakushev, I., Albert, N. L., van Berckel, B., Brendel, M., Cecchin, D., Fernandez, P. A., Fraioli, F., Guedj, E., Morbelli, S., Tolboom, N., Traub-Weidinger, T., Van Weehaeghe, D. and Barthel, H. (2023) FDA approval of lecanemab: the real start of widespread amyloid PET use? - the EANM Neuroimaging Committee perspective. Eur. J. Nucl. Med. Mol. Imaging 50, 1553-1555. https://doi.org/10.1007/s00259-023-06177-5
  139. Wang, G., Zhao, Z., Ren, B., Yu, W., Zhang, X., Liu, J., Wang, L., Si, D. and Yang, M. (2022) Exenatide exerts a neuroprotective effect against diabetic cognitive impairment in rats by inhibiting apoptosis: Role of the JNK/c-JUN signaling pathway. Mol. Med. Rep. 25, 111.
  140. Wattmo, C., Londos, E. and Minthon, L. (2014) Risk factors that affect life expectancy in Alzheimer's disease: a 15-year follow-up. Dement. Geriatr. Cogn. Disord. 38, 286-299. https://doi.org/10.1159/000362926
  141. Wattmo, C., Wallin, A. K., Londos, E. and Minthon, L. (2011) Predictors of long-term cognitive outcome in Alzheimer's disease. Alzheimers Res. Ther. 3, 23.
  142. Wu, C. L. and Wen, S. H. (2016) A 10-year follow-up study of the association between calcium channel blocker use and the risk of dementia in elderly hypertensive patients. Medicine (Baltimore) 95, e4593.
  143. Yang, P. and Sun, F. (2021) Aducanumab: the first targeted Alzheimer's therapy. Drug Discov. Ther. 15, 166-168. https://doi.org/10.5582/ddt.2021.01061
  144. Yokomichi, H., Nagai, A., Hirata, M., Kiyohara, Y., Muto, K., Ninomiya, T., Matsuda, K., Kamatani, Y., Tamakoshi, A. and Kubo, M. (2017) Serum glucose, cholesterol and blood pressure levels in Japanese type 1 and 2 diabetic patients: BioBank Japan. J. Epidemiol. 27, S92-S97. https://doi.org/10.1016/j.je.2016.12.013
  145. Zapater, P., Novalbos, J., Gallego-Sandin, S., Hernandez, F. T. and Abad-Santos, F. (2004) Gender differences in angiotensin-converting enzyme (ACE) activity and inhibition by enalaprilat in healthy volunteers. J. Cardiovasc. Pharmacol. 43, 737-744. https://doi.org/10.1097/00005344-200405000-00018
  146. Zhou, B., Zissimopoulos, J., Nadeem, H., Crane, M. A., Goldman, D. and Romley, J. A. (2021) Association between exenatide use and incidence of Alzheimer's disease. Alzheimers Dement. (N. Y.) 7, e12139.
  147. Zissimopoulos, J. M., Barthold, D., Brinton, R. D. and Joyce, G. (2017) Sex and race differences in the association between statin use and the incidence of Alzheimer disease. JAMA Neurol. 74, 225-232. https://doi.org/10.1001/jamaneurol.2016.3783